Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

Abstract

Among patients with type 2 diabetes and stage 2 to 4 CKD with moderately elevated albuminuria or stage 1 or 2 CKD with severely elevated albuminuria, finerenone therapy improved cardiovascular outcomes as compared with placebo. (Funded by Bayer; FIGARO-DKD ClinicalTrials.gov number, NCT02545049.).

Affiliated Institutions

Related Publications

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

George L. Bakris , Rajiv Agarwal , Stefan D. Anker +8 more

In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo. (Funded by Bayer; FIDELIO-...

2020 New England Journal of Medicine 2232 citations

Dapagliflozin in Patients with Chronic Kidney Disease

Hiddo J.L. Heerspink , Bergur V. Stefánsson , Ricardo Correa‐Rotter +11 more

Among patients with chronic kidney disease, regardless of the presence or absence of diabetes, the risk of a composite of a sustained decline in the estimated GFR of at least 50...

2020 New England Journal of Medicine 4549 citations

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Christoph Wanner , Silvio E. Inzucchi , John M. Lachin +7 more

In patients with type 2 diabetes at high cardiovascular risk, empagliflozin was associated with slower progression of kidney disease and lower rates of clinically relevant renal...

2016 New England Journal of Medicine 3470 citations

Cardiovascular Disease in Chronic Kidney Disease

Joachim Jankowski , Jürgen Floege , Danilo Fliser +2 more

Patients with chronic kidney disease (CKD) exhibit an elevated cardiovascular risk manifesting as coronary artery disease, heart failure, arrhythmias, and sudden cardiac death. ...

2021 Circulation 1565 citations

Reduction in Cardiovascular Events During Pravastatin Therapy

Robert P. Byington , J. Wouter Jukema , Jukka T. Salonen +5 more

Background It has been documented that the HMG coenzyme A reductase inhibitors, or statins, can decrease cardiovascular events and mortality in patients with clinical coronary d...

1995 Circulation 282 citations

Publication Info

Year: 2021
Type: article
Volume: 385
Issue: 24
Pages: 2252-2263
Citations: 1309
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1309

OpenAlex

Cite This

APA Style

                            
                                
                                    Bertram Pitt, 
                                
                                    Gerasimos Filippatos, 
                                
                                    Rajiv Agarwal
                                
                                et al.
                            
                            (2021). 
                            Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. 
                            New England Journal of Medicine
                            , 385
                            (24)
                            , 2252-2263.
                            https://doi.org/10.1056/nejmoa2110956
                        

Identifiers

DOI: 10.1056/nejmoa2110956